[CAR-T cell therapy in clinical practice].

Area of Science:

• Oncology
• Immunotherapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is effective for relapsed/refractory B-cell malignancies.
• Five CAR-T products are approved and widely used in Japan.
• CAR-T therapy involves complex, multi-step processes requiring optimization.

Purpose of the Study:

• To review the current clinical application of CAR T-cell therapy in Japan.
• To discuss practical considerations for CAR T-cell treatment delivery.
• To examine CAR T-cell therapy's role alongside emerging treatments.

Main Methods:

• Review of current clinical practices and literature on CAR T-cell therapy in Japan.
• Analysis of treatment delivery steps: T-cell collection, manufacturing, bridging, infusion, and adverse event management.
• Comparative assessment of CAR T-cell therapy with other novel therapeutic options.

Main Results:

• CAR T-cell therapy has achieved significant adoption in Japan for specific hematologic malignancies.
• Optimization is critical across all stages of CAR T-cell therapy delivery.
• Post-treatment management and addressing disease relapse are key challenges.

Conclusions:

• CAR T-cell therapy is a vital treatment option in Japan for certain blood cancers.
• Accumulating clinical experience and evidence for post-treatment care are essential.
• Understanding CAR T-cell therapy's place among evolving treatments is crucial for future strategies.